Last Updated : Sep 03, 2020 11:04 AM IST | Source: Reuters
Sanofi and GSK launch trial for COVID-19 protein-based vaccine
Sanofi and GSK said in a joint statement on Thursday they had started the "Phase 1/2" trial for their adjuvanted COVID-19 vaccine, which they hope to make available across the world.
French drugmaker Sanofi and its British peer GSK have started a clinical...
more... trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments against the coronavirus pandemic.
Sanofi and GSK said in a joint statement on Thursday they had started the "Phase 1/2" trial for their adjuvanted COVID-19 vaccine, which they hope to make available across the world.
This vaccine candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines with GSK's established pandemic adjuvant technology.
source url:
click here